BrainswayBWAY
Market Cap: $137M
About: BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Employees: 106
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
10% more capital invested
Capital invested by funds: $19.8M [Q1] → $21.7M (+$1.93M) [Q2]
0.51% less ownership
Funds ownership: 11.25% [Q1] → 10.74% (-0.51%) [Q2]
7% less funds holding
Funds holding: 29 [Q1] → 27 (-2) [Q2]
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 120 / 284 met price target | 95%upside $16 | Buy Maintained | 8 Aug 2024 |
Northland Capital Markets Carl Byrnes 50% 1-year accuracy 2 / 4 met price target | 34%upside $11 | Outperform Maintained | 7 Aug 2024 |
Financial journalist opinion
Based on 11 articles about BWAY published over the past 30 days